Abstract
Predicting individual response to drug therapy has long been a goal of personalized medicine in every therapeutic area. The mapping of the human genome and subsequent advancements in genetic technology had raised the public expectation that personalized drug therapy would come sooner than later. However, with barriers and logistical challenges existing at multiple levels, achieving this goal remains years away. Knowledge gap in healthcare professionals has always been cited as a significant barrier in clinical implementation of pharmacogenomics. Yet, to overcome the spectrum of challenges and for personalized medicine to succeed, there needs to be a rethinking of expanding the educational scope to include all stakeholders within the personalized medicine innovation ecosystem, rather than “narrowly” focusing on simply educating current and future health practitioners. Personalized medicine can only be achieved with all stakeholders in the field, under the rubric of a vision of a “knowledge ecosystem”, working together, and occasionally accepting a paradigm change in their current approaches to implementation. If postgenomics personalized medicine is to embrace systems pharmacology as a core tenet, it seems essential that such broader vision should be extended to field of education as well.
Keywords: Education, healthcare professionals, innovation ecosystem, personalized medicine, public health pharmacogenomics, stakeholders, systems pharmacology.
Current Pharmacogenomics and Personalized Medicine
Title:Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the “Know-Do” Gap Across the Personalized Medicine Innovation Ecosystem
Volume: 10 Issue: 4
Author(s): Y. W. Francis Lam
Affiliation:
Keywords: Education, healthcare professionals, innovation ecosystem, personalized medicine, public health pharmacogenomics, stakeholders, systems pharmacology.
Abstract: Predicting individual response to drug therapy has long been a goal of personalized medicine in every therapeutic area. The mapping of the human genome and subsequent advancements in genetic technology had raised the public expectation that personalized drug therapy would come sooner than later. However, with barriers and logistical challenges existing at multiple levels, achieving this goal remains years away. Knowledge gap in healthcare professionals has always been cited as a significant barrier in clinical implementation of pharmacogenomics. Yet, to overcome the spectrum of challenges and for personalized medicine to succeed, there needs to be a rethinking of expanding the educational scope to include all stakeholders within the personalized medicine innovation ecosystem, rather than “narrowly” focusing on simply educating current and future health practitioners. Personalized medicine can only be achieved with all stakeholders in the field, under the rubric of a vision of a “knowledge ecosystem”, working together, and occasionally accepting a paradigm change in their current approaches to implementation. If postgenomics personalized medicine is to embrace systems pharmacology as a core tenet, it seems essential that such broader vision should be extended to field of education as well.
Export Options
About this article
Cite this article as:
Lam W. Francis Y., Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the “Know-Do” Gap Across the Personalized Medicine Innovation Ecosystem, Current Pharmacogenomics and Personalized Medicine 2012; 10 (4) . https://dx.doi.org/10.2174/187569212803901828
DOI https://dx.doi.org/10.2174/187569212803901828 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Option of Plasmid-DNA Based Gene Transfer
Current Topics in Medicinal Chemistry A Review of Surgical Options to Preserve Fertility in the Treatment of Early Cervical Cancer
Current Women`s Health Reviews Telomere DNA Binding, Cleavage and Anticancer Activity of [Cu(phendione)(Hpyramol)Cl]
Current Chemical Biology Conjugation of Peptides to Antisense Interleukin-6 Via Click Chemistry
Current Medicinal Chemistry Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng
Medicinal Chemistry PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents In Vitro Study of UGT Metabolism and Permeability of Orientin and Isoorientin, Two Active flavonoid C-glycosides
Drug Metabolism Letters Dihydroresveratrol Type Dihydrostilbenoids: Chemical Diversity, Chemosystematics, and Bioactivity
Current Medicinal Chemistry Pegylated Naloxone in the Treatment of Persistent Opioid-Induced Constipation in Patients with Hematological Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Protein & Peptide Letters The p53-Estrogen Receptor Loop in Cancer
Current Molecular Medicine Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Targeted Ultrasound Imaging of Cancer: An Emerging Technology on its Way to Clinics
Current Pharmaceutical Design A Unique Intracellular, Extracellular and Transmembrane Circulation of Potassium Ions in the Auditory Inner Ear as an Anticarcinogenic Principle? Part 1
Inflammation & Allergy - Drug Targets (Discontinued) Treatment of Allergic Asthma by Targeting Transcription Factors Using Nucleic-Acid Based Technologies
Current Pharmaceutical Design Human Serum Albumin Conjugated Biomolecules for Cancer Molecular Imaging
Current Pharmaceutical Design Indole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection
Current Drug Metabolism